Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.

British journal of haematology - 1 Dec 2024

Kondo Takeshi

Abstract excerpt

The prognosis for patients with relapsed/refractory or measurable (minimal) residual disease-positive Philadelphia chromosome (Ph)-positive acute lymphoblastic leukaemia (ALL) is poor. Currently, ponatinib is the only approved tyrosine kinase inhibitor (TKI) that is effective for Ph-positive ALL with the T315I mutation. Although the report by Liu et al. is a retrospective observational study, it offers prospects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Imidazoles
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Philadelphia Chromosome

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Protein Kinase Inhibitors

Share to Pyridazines

Source

Identifiers

PMID: 39425572
DOI: 10.1111/bjh.19845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.PMID 39425572Read ↗

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single CenterSemantic proximity Read ↗

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registrySemantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registrySemantic proximity Read ↗

How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adultsSemantic proximity Read ↗

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Olverembatinib: First Approval.Semantic proximity Read ↗

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term resultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.